Added to YB: 2025-11-14
Pitch date: 2025-11-09
MEDCL.PA [bullish]
MedinCell S.A.
-13.06%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France.
Market Cap
EUR 910.1M
Pitch Price
EUR 31.70
Price Target
N/A
Dividend
N/A
EV/EBITDA
-96.53
P/E
-44.20
EV/Sales
32.66
Sector
Pharmaceuticals
Category
growth
Show full summary:
MedinCell's 'Shift to Growth' strategy validated; blockbuster drug Olanzapine expected in 2026
MEDCL.PA: UZEDY sales hit $136M (+82% YOY), targeting $190-200M 2025 with 5-9% royalties to MedinCell. Olanzapine LAI 'blockbuster' potential $1.5-2.9B market, FDA filing Q4 2025, approval/launch end 2026. AbbVie partnership worth $315M+ milestones. Operational profitability targeted 2026-27.
Read full article (3 min)